Early detection of poor outcome in patients with metastatic colorectal cancer: tumor kinetics evaluated by circulating tumor cells

hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms

[1]  C. Nicolazzo,et al.  Impact of chronic exposure to bevacizumab on EpCAM-based detection of circulating tumor cells. , 2015, Chinese journal of cancer research = Chung-kuo yen cheng yen chiu.

[2]  N. Petrelli,et al.  A review of the evolution of systemic chemotherapy in the management of colorectal cancer. , 2015, Clinical colorectal cancer.

[3]  G. Mazzini,et al.  Circulating endothelial cells and their subpopulations: role as predictive biomarkers in antiangiogenic therapy for colorectal cancer. , 2015, Clinical colorectal cancer.

[4]  S. Sleijfer,et al.  Circulating tumor cell enumeration by the CellSearch system: the clinician's guide to breast cancer treatment? , 2015, Cancer treatment reviews.

[5]  Jing Liu,et al.  Relationship between circulating tumor cells and tumor response in colorectal cancer patients treated with chemotherapy: a meta-analysis , 2014, BMC Cancer.

[6]  Robert B Livingston,et al.  Circulating tumor cells and response to chemotherapy in metastatic breast cancer: SWOG S0500. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  C. Boni,et al.  Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer. , 2014, The New England journal of medicine.

[8]  P. Paterlini-Bréchot,et al.  Isolation, detection, and immunomorphological characterization of circulating tumor cells (CTCs) from patients with different types of sarcoma using isolation by size of tumor cells: a window on sarcoma-cell invasion , 2014, OncoTargets and therapy.

[9]  E. Van Cutsem,et al.  Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  Hartmut Link,et al.  FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. , 2014, The Lancet. Oncology.

[11]  A. Zullo,et al.  Circulating tumor cells count predicts survival in colorectal cancer patients. , 2014, Journal of gastrointestinal and liver diseases : JGLD.

[12]  T. Rikiyama,et al.  Molecular biomarkers for the detection of metastatic colorectal cancer cells. , 2014, World journal of gastroenterology.

[13]  Andreas Trumpp,et al.  Serial enumeration of circulating tumor cells predicts treatment response and prognosis in metastatic breast cancer: a prospective study in 393 patients , 2014, BMC Cancer.

[14]  T. Yap,et al.  Circulating Tumor Cells: A Multifunctional Biomarker , 2014, Clinical Cancer Research.

[15]  E. Cortesi,et al.  Clinical utility of circulating tumor cell counting through CellSearch®: the dilemma of a concept suspended in Limbo , 2014, OncoTargets and therapy.

[16]  I. Thompson,et al.  Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  Caroline Dive,et al.  Molecular analysis of circulating tumour cells—biology and biomarkers , 2014, Nature Reviews Clinical Oncology.

[18]  P. Lorigan,et al.  Prevalence and heterogeneity of circulating tumour cells in metastatic cutaneous melanoma , 2014, Melanoma research.

[19]  A. Abad,et al.  Prognostic value of the combination of circulating tumor cells plus KRAS in patients with metastatic colorectal cancer treated with chemotherapy plus bevacizumab. , 2013, Clinical colorectal cancer.

[20]  J. Tabernero,et al.  Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. , 2013, The New England journal of medicine.

[21]  S. Matsusaka,et al.  Circulating tumor cell (CTC) count and epithelial growth factor receptor expression on CTCs as biomarkers for cetuximab efficacy in advanced colorectal cancer. , 2013, Anticancer research.

[22]  L. Frati,et al.  Circulating tumor cells in metastatic colorectal cancer: do we need an alternative cutoff? , 2013, Journal of Cancer Research and Clinical Oncology.

[23]  Kazunori Otsuka,et al.  Practical utility of circulating tumour cells as biomarkers in cancer chemotherapy for advanced colorectal cancer. , 2013, Anticancer research.

[24]  C. Punt,et al.  Relationship among circulating tumor cells, CEA and overall survival in patients with metastatic colorectal cancer. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[25]  Tobias M. Gorges,et al.  Circulating tumor cells as therapy-related biomarkers in cancer patients , 2013, Cancer Immunology, Immunotherapy.

[26]  M. Serdar,et al.  The utility of tumor markers CA 125, CA 15-3, and CA 19-9 in assessing the response to therapy in pulmonary and pleural tuberculosis , 2012, OncoTargets and Therapy.

[27]  G. Breier,et al.  Prognostic and predictive value of circulating tumor cell analysis in colorectal cancer patients , 2012, Journal of Translational Medicine.

[28]  G. Chang.  Challenge of primary tumor management in patients with stage IV colorectal cancer. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  B. Chauffert,et al.  Clinical value of circulating endothelial cell levels in metastatic colorectal cancer patients treated with first-line chemotherapy and bevacizumab. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[30]  C. Tournigand,et al.  Therapeutic strategy in unresectable metastatic colorectal cancer , 2012, Therapeutic advances in medical oncology.

[31]  T. Molina,et al.  Morphological analysis of circulating tumour cells in patients undergoing surgery for non‐small cell lung carcinoma using the isolation by size of epithelial tumour cell (ISET) method , 2012, Cytopathology : official journal of the British Society for Clinical Cytology.

[32]  Caroline Dive,et al.  Analysis of Circulating Tumor Cells in Patients with Non-small Cell Lung Cancer Using Epithelial Marker-Dependent and -Independent Approaches , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[33]  J. Schellens,et al.  Circulating tumor cells as pharmacodynamic biomarker in early clinical oncological trials. , 2011, Cancer treatment reviews.

[34]  D. Planchard,et al.  A direct comparison of CellSearch and ISET for circulating tumour-cell detection in patients with metastatic carcinomas , 2011, British Journal of Cancer.

[35]  X. Pivot,et al.  Clinical value of circulating endothelial cells and circulating tumor cells in metastatic breast cancer patients treated first line with bevacizumab and chemotherapy. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[36]  I. Nagtegaal,et al.  Circulating tumour cells early predict progression-free and overall survival in advanced colorectal cancer patients treated with chemotherapy and targeted agents. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[37]  J. Stebbing,et al.  Circulating tumour cells as more than prognostic markers. , 2009, The Lancet. Oncology.

[38]  V. Georgoulias,et al.  Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[39]  C. Punt,et al.  Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancer. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[40]  D. Sargent,et al.  Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  Dongsheng Tu,et al.  K-ras mutations and benefit from cetuximab in advanced colorectal cancer. , 2008, The New England journal of medicine.

[42]  K. Pienta,et al.  Circulating Tumor Cells Predict Survival Benefit from Treatment in Metastatic Castration-Resistant Prostate Cancer , 2008, Clinical Cancer Research.

[43]  Michael Morse,et al.  Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  S. Yun,et al.  Pulmonary resection for metastases from colorectal cancer: prognostic factors and survival , 2007, International Journal of Colorectal Disease.

[45]  Leon W.M.M. Terstappen,et al.  Circulating Tumor Cells versus Imaging—Predicting Overall Survival in Metastatic Breast Cancer , 2006, Clinical Cancer Research.

[46]  Charles Cha,et al.  Liver resection for metastatic colorectal cancer in the age of neoadjuvant chemotherapy and bevacizumab. , 2006, Clinical colorectal cancer.

[47]  Alison Stopeck,et al.  Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[48]  Alison Stopeck,et al.  Circulating tumor cells, disease progression, and survival in metastatic breast cancer. , 2004, The New England journal of medicine.

[49]  W. Scheithauer,et al.  Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[50]  M Tod,et al.  A critical review of the analytical approaches for circulating tumor biomarker kinetics during treatment. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[51]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.

[52]  K. Schütze,et al.  Isolation by size of epithelial tumor cells : a new method for the immunomorphological and molecular characterization of circulatingtumor cells. , 2000, The American journal of pathology.